Valneva (VALN)

• Market cap: $584M
• 1 day: -1.71%
• 5 days: -8.91%
• 1 month: -5.51%
• 3 months: 20.76%
• 6 months: 8.38%
• Year to date: 34.32%
• 1 year: -14.90%
• 5 years: -77.64%
• 10 years: -77.64%
• Sector: Healthcare
• Industry: Biotechnology

About: Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.

Employees: 713

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

20% more funds holding

Funds holding: 10 [Q3] → 12 (+2) [Q4]

0% more ownership

Funds ownership: 0.44% [Q3] → 0.44% (+0%) [Q4]

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

27% less capital invested

Capital invested by funds: $4.35M [Q3] → $3.16M (-$1.19M) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $15 137% upside
• Avg. target: $16 152% upside
• High target: $17 168% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Edward White 22% 1-year accuracy 32 / 148 met price target	168% upside $17	Buy Reiterated	15 Apr 2025
Guggenheim Dana Flanders 0% 1-year accuracy 0 / 1 met price target	137% upside $15	Buy Maintained	24 Mar 2025